Listed by the USPTO as HUMPHRIES, NICHOLAS ADAM
Tech Center 1600 • Art Units: 1631
This examiner grants 34% of resolved cases
HUMPHRIES, NICHOLAS ADAM works in Tech Center 1600 and Art Unit 1631. The profile includes 38 resolved cases, an allowance rate of 34.2%, and a median of 1379 days to allowance. The interview lift is 76.6%, which makes examiner discussion a particularly important consideration, although the limited case base requires caution in interpreting the pattern.
Axenoll Life Sciences AG, Mayo Foundation for Medical Education and Research, and Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. are the listed companies. MARSHALL, GERSTEIN & BORUN LLP, Kilpatrick Townsend & Stockton LLP - West Coast, and Nixon Peabody LLP are the listed firms. Counsel should prepare interviews carefully and preserve multiple claim strategies.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17774834 | EPHA3 DIRECTED CAR-T CELLS FOR TREATMENT OF TUMORS | Non-Final OA | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH |
| 18009071 | PROCESS FOR PRODUCING CARRIER PARTICLES FOR THE CULTIVATION OF BIOLOGICAL CELLS, CARRIER PARTICLES AND THEIR USE | Non-Final OA | Fraunhofer-Gesellschaft zur Foerderung der angewandten Forschung e. V. |
| 17627229 | METHODS AND COMPOSITIONS FOR GENE DELIVERY | Final Rejection | President And Fellows Of Harvard College |
| 18084105 | METHOD FOR REDUCING OFF-TARGET UPTAKE OR ACCUMULATION OF AGENTS | Non-Final OA | The Regents of the University of Colorado, A Body Corporate |
| 17632063 | TARGETED GENE THERAPY TO TREAT NEUROLOGICAL DISEASES | Non-Final OA | Cornell University |
| 18350986 | CELLS AND METHOD OF CELL CULTURE | Final Rejection | Pfizer Inc. |
| 18266951 | CULTURE MATERIAL AND USE THEREOF | Final Rejection | MITSUI CHEMICALS, INC. |
| 18042726 | VIRAL VECTORS ENCODING GLP-1 RECEPTOR AGONIST FUSIONS AND USES THEREOF IN TREATING METABOLIC DISEASES | Final Rejection | The Trustees of the University of Pennsylvania |
| 17641254 | EX VIVO LYMPH NODE AND USES THEREOF | Non-Final OA | UNIVERSITY OF DELAWARE |
| 18170296 | COMPOSITIONS AND METHODS FOR TREATMENT OF SPINAL MUSCULAR ATROPHY | Non-Final OA | The University of Hong Kong |
| 18361790 | METHODS AND COMPOSITIONS FOR CRYOPRESERVATION OF IMMUNE CELLS | Final Rejection | TAKEDA PHARMACEUTICAL COMPANY LIMITED |
| 18286709 | RATIONAL POLYPLOID AAV VIRIONS THAT CROSS THE BLOOD BRAIN BARRIER AND ELICIT REDUCED HUMORAL RESPONSE | Non-Final OA | ASKBIO INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy34.2% of resolved applications examined by Nicholas Adam Humphries were allowed (38 resolved cases), compared with 28.4% across Art Unit 1631 over the last five years.
This examiner's interview lift is +76.6 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Nicholas Adam Humphries took 1,379 days on average from filing to allowance.
Nicholas Adam Humphries examines applications in Art Unit 1631 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
